SymaIqbalMD

Clinical Trials

• S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma Start of enrollment: 2003 Sep 01

  Completed

  Phase 2

• S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer Start of enrollment: 2004 Oct 01

  Completed

  Phase 2

• SB-715992 in Treating Patients With Advanced or Metastatic Colorectal Cancer Start of enrollment: 2005 Jan 01

  Completed

  Phase 2

• S0413 Lapatinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer Start of enrollment: 2004 Dec 01

  Completed

  Phase 2

• Capecitabine and Gemcitabine in Patients With Metastatic Colorectal Cancer Start of enrollment: 2004 Mar 01

  Completed

  Phase 2

• Genes as Predictors of Response to Gemcitabine, Docetaxel, and Capecitabine (GTX) in Metastatic or Unresectable Pancreatic Cancer. Start of enrollment: 2005 Feb 01

  Terminated

  Not Applicable

• Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere) Start of enrollment: 2000 Dec 01

  Completed

  Phase 1

• A Study of Irinotecan, Cisplatin and Celebrex in Patients With Metastatic or Unresectable Esophageal Cancer Start of enrollment: 2003 Oct 01

  Terminated

  Phase 2

• Study of Irinotecan Administered as a Continuous Infusion and Radiation Therapy for Upper Gastrointestinal Cancers Start of enrollment: 2000 Dec 01

  Completed

  Phase 1

• Clinical and Pharmacokinetic Trial of Intra-Abdominal Irinotecan Start of enrollment: 1999 Sep 01

  Completed

  Phase 1

• Study of Irinotecan and Docetaxel in Patients With Metastatic or Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma Start of enrollment: 2005 Apr 14

  Completed

  Phase 2

• A Phase II Study of Intra-arterial Chemotherapy With Cisplatin and Mitomycin-C in Patients With Hepatocellular Carcinoma Start of enrollment: 2004 Oct 18

  Unknown status

  Phase 2

• Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer Start of enrollment: 2004 Dec 28

  Active, not recruiting

  Phase 2

• Study of 5-Fluorouracil and Leucovorin and Intra-abdominal Floxuridine Chemoradiation in Patients With Fully Resected Locally Advanced Gastric Adenocarcinoma Start of enrollment: 2003 Nov 01

  Completed

  Phase 2

• FOLFIRI + Bevacizumab With or Without Dalteparin in First Line Treatment of Advanced Colorectal Cancer Start of enrollment: 2006 May 01

  Terminated

  Phase 2

• A Pilot Study of PPX in Women With Metastatic Colorectal Cancer Start of enrollment: 2008 Jan 01

  Completed

  Phase 1

• Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery Start of enrollment: 2010 Apr 05

  Active, not recruiting

  Phase 3

• S0820, Adenoma and Second Primary Prevention Trial Start of enrollment: 2013 Aug 23

  Active, not recruiting

  Phase 3

• S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer Start of enrollment: 2012 Feb 01

  Completed

  Phase 2

• Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors Start of enrollment: 2013 Sep 20

  Active, not recruiting

  Phase 2

• Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors Start of enrollment: 2016 Aug 16

  Completed

  Phase 2

• Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer Start of enrollment: 2015 May 13

  Active, not recruiting

  Phase 2

• A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer Start of enrollment: 2015 Jul 07

  Completed

  Phase 2

• Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors Start of enrollment: 2020 Aug 06

  Active, not recruiting

  Phase 2

• Join now to see all